- Anti-hypertensive treatment (AHT) with renin-angiotensin system (RAS)-acting angiotensin-II receptor blockers (ARBs), in addition to lowering BP, may reduce Alzheimer’s disease (AD) risk, particularly in white and black women and white men.
Why this matters
- Finding suggests that use of certain anti-hypertensives may offer benefits in patients with AD in addition to their BP lowering effects.
- This retrospective cohort study compared AD diagnosis rates across 6 different AHT users (n=13,43,334) and 65 years of age or older (4,215,338 person-years).
- Risks for AD were compared between RAS and non-RAS AHT users, and between angiotensin converting enzyme inhibitors (ACEIs) and ARB users by sex and race/ethnicity.
- Funding: National Institutes of Health.
- Compared with non-RAS-acting AHTs, RAS-acting AHTs were associated with significantly lower risk for AD in men (OR, 0.931; 95% CI, 0.895-0.969) vs women (OR, 0.985; 95% CI, 0.963-1.007).
- This significant association was mainly driven by white males (OR, 0.932; 95% CI, 0.892-0.974).
- ARBs were superior to ACEIs in lowering AD risk in both white men and white and black women:
- Men (ARB users: OR, 0.834; 95% CI, 0.788-0.884 and ACEI users: OR, 0.978; 95% CI, 0.939-1.019).
- Women (ARB users: OR, 0.941; 95% CI, 0.913-0.969 and ACEI users: OR, 1.022; 95% CI, 0.997-1.048).
- There was no significant association between RAS-acting AHTs and AD risk in Hispanic men and women.
- AHT use and AD were imprecisely measured.